Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

This trial is testing a drug called ceralasertib (AZD6738) — either alone or combined with olaparib or durvalumab — in people with advanced solid tumors that have specific genetic features (missing certain proteins called ARID1A or ATM) that may make the cancer more vulnerable to this drug. **You may be eligible if...** - You are 18 or older with an advanced or metastatic solid tumor that has progressed after at least one prior treatment - Your tumor is one of several specific cancer types including kidney, bladder, pancreatic, prostate, endometrial, or ovarian cancer, or other solid tumors - Your tumor tissue shows a specific genetic marker (loss of ARID1A or ATM protein) - Your cancer can be measured on scans - You have adequate blood counts and organ function **You may NOT be eligible if...** - You have had certain prior treatments that conflict with this study - You have active brain metastases that are unstable - You have serious heart problems, active infections, or HIV/hepatitis B/C - You have had a prior organ transplant - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.